alexa Effect Of Denosumab Versus Zoledronic Acid On Calcium Levels In Cancer Patients With Bone Metastasis: An Observational Retrospective Cohort Study
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

9th Annual European Pharma Congress
June 26-28, 2017 Madrid, Spain

Sahar S Nasser, Arwa O Sahal, Anas A Hamad and Shereen A ElAzzazy
Hamad Medical Corporation, Qatar
Posters & Accepted Abstracts: Pharmaceut Reg Affairs
DOI: 10.4172/2167-7689-C1-025
Abstract
Background: Bone-targeting agents (BTA) like zoledronic acid (ZA) and denosumab (DE) are approved for prevention of skeletalrelated events (SREs) in patients with bone metastases (BM) including hypercalcemia of malignancy (HCM). Hypocalcemia has been observed with both ZA and DE. However, studies showed a higher incidence of hypocalcemia with denosumab. International guidelines do not favor one BTA over the other. Due to the differences in patients’ characteristics and treatment related factors; hypocalcemia incidence might differ in varying cancer settings. Primary Objective: Primary objective of the study is to identify the incidence of hypercalcemia and hypocalcemia in ZA and DE groups. Secondary Objective: Secondary objective is to identify the correlation between calcium supplement and calcium level control. Methods: An observational retrospective cohort study was conducted by reviewing patients’ electronic records, laboratory and medication reports from August 1st 2015 till July 31st 2016. Adult cancer patients diagnosed with BM secondary to a solid tumor or multiple myelomas and receiving either ZA or DE were included. Other indications for BTA were excluded. BTA administration visits were collected, evaluated and analyzed. Results: A total of 271 patients (1367 visits) were included in our study. Over incidence of hypocalcemia in DE group compared to ZA was (4.1% vs. 3%, OR=0.72, CI 95% [0.43–1.19]). Hypercalcemia was reported in both groups (3.5% vs. 5.3% respectively, CI 95% [0.97–2.4]). Breast cancer was the most common malignancy associated with hypocalcemia (70%) followed by (10%) in both prostate cancer and multiple myelomas. Patients received calcium supplement were 23% less likely to develop hypocalcemia (RR=0.77, CI 95% [0.48–1.23]). Conclusion: Despite hypocalcemia was common in DE group, it was not statistically significant. Adequate calcium intake substantially reduces the risk of hypocalcemia. Our results highlight the importance of preventing hyper and hypocalcemia upon BTAs initiation and during treatment by regular monitoring of calcium levels, and providing calcium supplements accordingly.
Biography

Sahar S Nasser has received her Bachelor’s degree in Pharmacy from Qatar University, College of Pharmacy (CCAPP accredited) in 2011. She began her pharmacy career at the National Center of Cancer Care and Research (NCCCR). She is also a Clinical Preceptor for undergraduate pharmacy students and got promoted to Senior Pharmacist in 2015. She has recently completed her Post-graduate year 1 (PGY1) Pharmacy Practice Residency in Hamad Medical Corporation (in candidate status for accreditation by ASHP). Her early-career focus was on patient centered care practice and medication safety. Throughout her career, she participated in various educational activities directed to healthcare providers, students and patients. Her main research interest is in improving cancer patients’ outcomes and cancer epidemiology.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords